NWBO could have chose to go the route of their own mfg capabilities even though that would have been the less ideal route to an existing, established CDMO, but they decided why not fund it so the CEO can build and own the CDMO from scratch. And like you said at the expense of the shareholder. Nice!
Complete response letters (CRL) can happen for various reasons including manufacturing. I'm not sure at this point in NWBO's financial state, they can survive a CRL given that they are living foot to mouth. Not saying it will happen, but that is the state of their finances. And if you have been investing in biotechs long enough, you know nothing is guaranteed in regulatory approvals even with clean data.
And 100% there are better companies that inform their shareholders and meet their timelines. Hopefully, UK submission is near and you can get out with some profit and still keep your sanity!
Market Data 
Markets 
AI
